Critical Limb Ischemia Market Report 2026

The critical limb ischemia market size has grown strongly in recent years. It will grow from $3.89 billion in 2025 to $4.25 billion in 2026 at a compound annual growth rate (CAGR) of 9.3%. The growth in the historic period can be attributed to high prevalence of peripheral artery disease, increasing diabetes incidence, aging population growth, reliance on surgical revascularization, delayed disease diagnosis.

The critical limb ischemia market size is expected to see strong growth in the next few years. It will grow to $6 billion in 2030 at a compound annual growth rate (CAGR) of 9%. The growth in the forecast period can be attributed to advancements in vascular devices, rising minimally invasive procedures, expansion of specialized vascular centers, growing awareness of limb preservation, improved diagnostic imaging access. Major trends in the forecast period include rising adoption of endovascular revascularization, increased use of drug-eluting devices, growth of limb salvage treatment approaches, expansion of multidisciplinary vascular care, focus on early diagnosis and intervention.

The rising investment in healthcare infrastructure is expected to drive the growth of the critical limb ischemia treatment market in the coming years. Healthcare infrastructure investment refers to the funding directed toward the development, enhancement, and upkeep of essential physical facilities, systems, and resources that support the delivery of healthcare services. Such investments play a crucial role in the treatment of critical limb ischemia by ensuring access to appropriate facilities, advanced equipment, and skilled resources needed for accurate diagnosis and effective treatment. For example, in May 2023, according to a report released by the Office for National Statistics, a UK-based government department, healthcare spending in the United Kingdom increased by 5.6 percent between 2022 and 2023, compared with a growth rate of 0.9 percent in 2022. Total healthcare expenditure in the UK reached approximately $317.63 billion (£292 billion) in 2023. Therefore, increasing investments in healthcare infrastructure are contributing to the growth of the critical limb ischemia treatment market.

Major companies operating in the critical limb ischemia treatment market are focusing on developing technologically advanced solutions, such as dissolving stents, to improve outcomes for patients affected by this severe form of peripheral artery disease. Dissolving stents, also known as bioresorbable stents, are designed to provide temporary structural support to narrowed arteries and gradually dissolve once the vessel has healed. For instance, in April 2024, Abbott Laboratories, a US-based medical device company, received approval from the US Food and Drug Administration for the Esprit BTK Everolimus Eluting Resorbable Scaffold System. This dissolving stent is intended for patients with chronic limb-threatening ischemia in arteries below the knee and represents the first FDA-approved dissolving stent for this condition in the United States. The stent is made from materials similar to those used in dissolvable sutures and is engineered to gradually resorb over approximately three years following implantation. It releases the immunosuppressive drug everolimus, which helps reduce the risk of artery re-narrowing and supports vessel healing.

In November 2023, Inari Medical, a US-based medical device company, acquired LimFlow SA for an undisclosed amount. Through this acquisition, Inari Medical seeks to expand its portfolio with innovative technologies that address unmet needs in chronic limb-threatening ischemia, with the goal of improving patient outcomes and supporting long-term growth. LimFlow SA is a Switzerland-based company that develops medical devices for the treatment of chronic limb-threatening ischemia.

Major companies operating in the critical limb ischemia market are Medtronic Plc, Boston Scientific Corporation, Abbott Laboratories, LimFlow SA, Micro Medical Solutions, Cardiovascular Systems Inc., Shanghai MicroPort Medical (Group) Co Ltd., B. Braun SE, Teva Pharmaceutical Industries Ltd., Cook Medical, Philips, BD, Penumbra Inc., Cardinal Health Inc., Teleflex Incorporated, AngioDynamics Inc., Endologix Inc., Terumo Corporation, MicroPort Scientific, Silk Road Medical, LeMaitre Vascular Inc., Merit Medical Systems Inc., Shockwave Medical, Avinger, Biomerics LLC, Intact Vascular Inc., Bluegrass Vascular Technologies, PQ Bypass, Rex Medical, Aortica Corporation.

North America was the largest region in the critical limb ischemia treatment market in 2025. The regions covered in the critical limb ischemia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the critical limb ischemia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the critical limb ischemia market by increasing costs of imported angioplasty balloons, stents, catheters, and surgical devices. Hospitals and vascular clinics in North America and Europe are most affected due to reliance on imported medical devices, while Asia-Pacific faces higher procurement costs. These tariffs are increasing treatment expenses. However, they are also encouraging domestic device manufacturing and regional supply chain development.

The critical limb ischemia market research report is one of a series of new reports that provides critical limb ischemia market statistics, including critical limb ischemia industry global market size, regional shares, competitors with a critical limb ischemia market share, detailed critical limb ischemia market segments, market trends and opportunities, and any further data you may need to thrive in the critical limb ischemia industry. This critical limb ischemia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Critical limb ischemia treatment involves restoring blood flow to areas affected by critical limb ischemia, a chronic condition in which blood supply to one or more limbs, such as the hands or legs, is severely reduced, leading to pain and numbness. Treatment includes diagnosis and management through medications, surgical procedures using medical devices, and other therapeutic approaches.

The main treatment types in the critical limb ischemia market include devices, drugs, and surgical interventions. Embolic protection devices are medical devices designed to capture blood and luminal debris, preventing plaque particles from traveling to distal vascular beds. The medications used include antihypertensive agents, antiplatelet drugs, antithrombotic agents, and others, which are administered across healthcare settings such as hospitals, clinics, and other care facilities.

The critical limb ischemia treatment market includes revenues earned by entities by providing angioplasty, stents and laser atherectomy treatment. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.